Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A retinal implant is giving sight back to the legally blind. The PRIMA photovoltaic subretinal implant, a 2mm microchip paired with smart glasses, is delivering real functional vision gains to patients with geographic atrophy. After 36 months, patients gained an average of six lines of visual acuity — and the improvements kept getting better over time.
A tiny chip in the back of the eye is changing lives. The PRIMA photovoltaic subretinal implant (Science Corporation) is offering new hope to patients with geographic atrophy (GA) — the leading cause of legal blindness in developed countries. The device pairs a surgically implanted 2mm microchip with specialized glasses that project near-infrared light onto the retina, converting it into electrical signals that travel to the brain via surviving retinal cells. No wires, no batteries — just a pocket-sized processor and a pair of glasses.
The PRIMAvera clinical trial enrolled 38 patients across five European countries, with follow-up of up to 36 months. Results were strong enough to earn the device a CE mark, and it is now being implanted commercially across Europe.
By the Numbers:
Why it matters: For patients with GA, current treatments can only slow progression — not restore vision. PRIMA is the first device to demonstrably return functional central vision, with gains that are durable and continue to improve over time. Future generations of the technology could push resolution and usability even further.